Clinically meaningful prolonged survival was demonstrated in both patient groups. A median overall survival of 52.5 months was achieved in a Phase 2 trial of the WT1 vaccine in adult patients with AML.
Clinically meaningful prolonged survival was demonstrated in both patient groups. A median overall survival of 52.5 months was achieved in a Phase 2 trial of the WT1 vaccine in adult patients with AML.